secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001665988-26-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q4 GAAP EPS $0.21, revenue $157.9M; guides FY2026 sales $600-610M
---------------------------------------------------------------------------

- Q4 revenue $157.9M (+2.8% reported, +10.0% organic); GAAP EPS $0.21 (vs $0.00); non-GAAP EPS $0.24; Adj. EBITDA $36.7M (+30%).
- Full year 2025 revenue $568.1M (-0.9% reported, +7.5% organic); GAAP EPS $0.33 (vs -$0.56); Adj. EPS $0.68 (+21.4%).
- FY2026 guidance: net sales $600-610M (6-7% growth); Adj. EPS $0.73-$0.77 (7-13% growth); cash from ops $82-87M.
- Q4 cash from operations $38M (+97% YoY); full year cash from ops up 92%; debt reduced by $29M in Q4.
- Launched PNS products StimTrial and TalisMann; added Megan Rosengarten as SVP/GM PNS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000166598826000010/0001665988-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000166598826000010/bvs-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001665988-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer